Grifols SA (GRFS) saw its stock soar 5.04% in the intraday trading session on Thursday, following the company's release of its Q4 2024 earnings report. The Spanish healthcare giant, specializing in plasma-derived therapies and diagnostics, reported record revenues and adjusted EBITDA for the year, driven by robust growth in its core Biopharma division.
The company's Biopharma segment, which includes its immunoglobulin (IG) franchise, emerged as a standout performer. In Q4, IVIG sales witnessed a remarkable 15.6% increase, while the subcutaneous IG market experienced an impressive 52% growth year-to-date. This strong momentum in plasma-derived therapies, coupled with a solid performance in albumin sales, solidified Grifols' position as a market leader in this domain.
Furthermore, Grifols made significant strides in strengthening its financial health. The company successfully reduced its leverage ratio from 6.8x in Q1 2024 to 4.6x by the end of the year, demonstrating improved debt management. Moreover, the company generated robust free cash flow, exceeding its initial guidance with a year-end result of €267 million.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。